Please try another search
Redwood Pharma AB engages in the development of ophthalmic drugs for medical needs in Sweden. Its lead development product is RP101, an eye drop that treats severe chronic dry eye disease in post-menopausal women; and RP501, a next generation smart hydrogel medical device for the treatment of mild dry eye. The company was founded in 2012 and is headquartered in Stockholm, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Hakan Magnusson | - | 2023 | Independent Director |
Tom Ronnlund | 51 | 2023 | Independent Director |
Martin Vidaeus | 57 | 2012 | Founder, CEO & Director |
Ulf Bjorklund | 67 | 2016 | Chairman & Chief Medical Officer |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review